18 studies found for:    "Stargardt macular degeneration" [DISEASE] OR NCT00254605 [ID-NUMBER] OR NCT01278277 [ID-NUMBER] OR NCT00060749 [ID-NUMBER] OR NCT00346853 [ID-NUMBER] OR NCT00420602 [ID-NUMBER]
Show Display Options
RSS Create an RSS feed from your search for:
"Stargardt macular degeneration" [DISEASE] OR NCT00254605 [ID-NUMBER] OR NCT01278277 [ID-NUMBER] OR NCT00060749 [ID-NUMBER] OR NCT00346853 [ID-NUMBER] OR NCT00420602 [ID-NUMBER]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting DHA Supplementation in Patients With STGD3
Condition: Dominantly Inherited Stargardt's Disease (STGD3)
Intervention: Dietary Supplement: Over the counter DHA/EPA dietary supplementation
2 Recruiting Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Conditions: Stargardt Disease;   Stargardt Macular Degeneration;   Stargardt Macular Dystrophy;   Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions: Drug: ALK-001;   Drug: Placebo
3 Active, not recruiting Saffron Supplementation in Stargardt's Disease
Conditions: Retinal Degeneration;   Genetic Disease;   Single-Gene Defects;   Macular Dystrophy
Interventions: Dietary Supplement: Saffron supplementation;   Other: placebo
4 Recruiting Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Condition: Stargardt Disease
Intervention: Drug: SAR422459
5 Completed Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-Like Macular Dystrophy
Condition: Macular Degeneration
Intervention: Drug: Docosahexaenoic Acid (DHA) Dietary Supplement
6 Enrolling by invitation A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration
Condition: Stargardt Disease
Intervention: Drug: SAR422459
7 Unknown  Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
Condition: Stargardt Disease
Intervention:
8 Completed Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
Condition: Macular Dystrophy, Corneal
Interventions: Drug: 4-Methylpyrazole;   Other: saline
9 Recruiting Retinal Imaging in Patients With Inherited Retinal Degenerations
Condition: Retinitis Pigmentosa
Intervention:
10 Active, not recruiting A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
Condition: Stargardt Disease
Intervention:
11 Recruiting The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Condition: Stargardt Disease
Intervention:
12 Recruiting Inherited Retinal Degenerative Disease Registry
Conditions: Eye Diseases Hereditary;   Retinal Disease;   Achromatopsia;   Bardet-Biedl Syndrome;   Bassen-Kornzweig Syndrome;   Batten Disease;   Best Disease;   Choroidal Dystrophy;   Choroideremia;   Cone Dystrophy;   Cone-Rod Dystrophy;   Congenital Stationary Night Blindness;   Enhanced S-Cone Syndrome;   Fundus Albipunctatus;   Goldmann-Favre Syndrome;   Gyrate Atrophy;   Juvenile Macular Degeneration;   Kearns-Sayre Syndrome;   Leber Congenital Amaurosis;   Refsum Syndrome;   Retinitis Pigmentosa;   Retinitis Punctata Albescens;   Retinoschisis;   Rod-Cone Dystrophy;   Rod Dystrophy;   Rod Monochromacy;   Stargardt Disease;   Usher Syndrome
Intervention:
13 Completed Phase 1 Safety Study of ALK-001 in Healthy Volunteers
Conditions: Stargardt Disease;   Age-related Macular Degeneration;   Other Retinal Dystrophies
Intervention: Drug: ALK-001 (No generic name)
14 Completed Microcurrent Stimulation to Treat Macular Degeneration
Conditions: Retinal Diseases;   Stargardt's Disease;   Retinitis Pigmentosa
Intervention:
15 Recruiting Stem Cell Ophthalmology Treatment Study
Conditions: Retinal Disease;   Macular Degeneration;   Hereditary Retinal Dystrophy;   Optic Nerve Disease;   Glaucoma
Interventions: Procedure: RB (Retrobulbar);   Procedure: ST (Subtenon);   Procedure: IV (Intravenous);   Procedure: IVIT (Intravitreal);   Procedure: IO (Intraocular)
16 Enrolling by invitation Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
Condition: Stargardt's Macular Dystrophy
Intervention: Biological: MA09-hRPE
17 Active, not recruiting Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Condition: Stargardt's Macular Dystrophy
Intervention: Biological: MA09-hRPE
18 Active, not recruiting Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
Condition: Stargardt's Macular Dystrophy
Intervention: Biological: MA09-hRPE

Indicates status has not been verified in more than two years